Treating and Preventing Adolescent Mental Health Disorders: Treating and Preventing Adolescent Mental Health Disorders

Home > Table of Contents

Book Title: Treating and Preventing Adolescent Mental Health Disorders > pp. [796]

UNDEFINED: AUTHORS

Treating and Preventing Adolescent Mental Health Disorders

Print ISBN 9780195173642, 2005
pp. [796]

Change

consensual theory of, in positive youth development field , 521

organizational readiness , 559

Character strengths , 510 , 527

Chemical dependency . See Substance use disorders

Chemical transmission

in anxiety disorders , 187

in drug addiction , 377–78

Child abuse

depression and , 14 , 15

neuroendocrine changes , 26

suicidal behavior and , 440

Child and Adolescent Service System Program (CASSP), 550

Child and Adolescent Trauma Screen (CATS), 234

Child Behavior Checklist (CBCL), 236

Child PTSD Symptom Scale (CPSS), 234–35

Child Trends , 515 , 518 t

Child welfare system, substance abuse identification , 565

Childhood Anxiety Sensitivity Index (CASI), 172 , 233–34

Children . See also Parent-child interaction

abuse of . See Child abuse

bipolar disorder in, versus adolescent-onset , 18

generalized anxiety disorder in , 195–98

major depressive disorder in

versus adolescent-onset , 4 , 7

antidepressants for , 43–47

psychosocial therapy , 34–42

obsessive-compulsive disorder in , 205–9

panic disorder in , 203–4

phobia in , 200–202

post-traumatic stress disorder in , 210–13

at risk for schizophrenia, longitudinal studies , 142 , 144 , 146–48 , 150 t, 153–54

schizophrenia in, event-related potentials in , 92–95 , 93 t

social anxiety disorder in , 192–93

weight loss interventions for , 316–17

CHRNA7, as schizophrenia susceptibility gene , 105

Cigarette smoking . See Smoking

Citalopram, for major depressive disorder , 42 , 44 , 45 t

Clarke program for prevention of depression , 63

Classical conditioning

in anxiety disorders , 170–71

in substance use disorders , 376–77

Climate, organizational , 558

Clinic-community intervention model for treatment development , 557

Clomipramine

for obsessive-compulsive disorder , 205 , 207

for panic disorder , 203

Clonazepam, for panic disorder , 202–3 , 218

Clonidine, for post-traumatic stress disorder , 213

Clozapine

for bipolar disorder , 53

for psychotic disorder and suicidal behavior , 127

for schizophrenia , 122 t, 123 t, 124 t, 126

for suicide attempters , 483

Club drugs , 372

Cocaine use , 349–53 , 352 t

alcohol and , 352

clinical aspects , 351–53 , 352 t

genetics , 388

medical complications , 353

treatment , 406–7

withdrawal , 352 , 352 t

Cognitive-behavioral analysis system of psychotherapy, for major depressive disorder , 47

Cognitive-behavioral therapy

for anorexia nervosa , 296

for anxiety disorders

developmental considerations , 186

education and skill-building , 185

exposure exercises , 185–86

history and rationale , 184–86

maintenance of gains , 213–14

mechanisms , 172

with pharmacotherapy , 187–88

recommendations , 214 t

research agenda , 251

for bipolar disorder , 48

for bulimia nervosa , 288–89 , 290–91 , 296–97

for eating disorders , 291 , 321–22

for generalized anxiety disorder , 189 t, 194 , 195–96

for major depressive disorder

in adults , 30–31 , 33

in children and adolescents , 34–38 , 35 t, 36 f, 37 t

in Latino youth , 39–40

with pharmacotherapy , 47–48

prevention programs , 38 , 62–65

symptomatic community samples , 38

for obsessive-compulsive disorder , 190t–191 t, 204–5 , 206–7

for panic disorder , 190 t, 202 , 203–4 , 237–38

for phobia , 190 t, 200–201

for post-traumatic stress disorder , 191 t, 209–10 , 211–13 , 237 , 244

for schizophrenia , 112–13 , 126

for separation anxiety disorder , 189t–190 t, 198–99

for social anxiety disorder , 189 t, 192–93

for substance use disorders , 397

for subsyndromal depression , 38

for suicidal adults , 477–78

for suicidal youth , 40 , 478 , 479t–480 t, 481

end p.796